The Avastin® biosimilars market is projected to witness noteworthy growth over the coming years

In 2020, revenues from the sales of Avastin®, Roche’s anti-VEGFA antibody based therapeutic, were observed to have declined by 25% due to competition from biosimilars, in the United States, Europe, Japan, and other nations where it is approved

For additional details, please visit
https://www.rootsanalysis.com/reports/avastin-biosimilars-pipeline-review-and-partnerships.html
The Avastin® biosimilars market is projected to witness noteworthy growth over the coming years In 2020, revenues from the sales of Avastin®, Roche’s anti-VEGFA antibody based therapeutic, were observed to have declined by 25% due to competition from biosimilars, in the United States, Europe, Japan, and other nations where it is approved For additional details, please visit https://www.rootsanalysis.com/reports/avastin-biosimilars-pipeline-review-and-partnerships.html
Avastin® (Bevacizumab) Biosimilars - Pipeline Review and Partnerships
AvastinR (Bevacizumab) Biosimilars - Pipeline Review and Partnerships report features an extensive study of the current market landscape and future potential...
WWW.ROOTSANALYSIS.COM
0 Comments 0 Shares
Sponsored